Company Overview
Snapshot
Founded in August 2005 by Yaakov Naparstek, ProtAb operates with 1–10 employees. The company has raised $8.9M across 3 funding rounds from 3 investors. ProtAb secured a grant from the Office of the Chief Scientist.
Business overview
ProtAb Ltd develops therapeutic agents that modulate cytokine regulation to treat autoimmune and inflammatory diseases. Its core product, Prozumab, is a monoclonal antibody with a novel mechanism of action, currently in late-stage preclinical development for inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA). The company operates within the Pharmaceuticals sector, focusing on drugs discovery and development for the healthcare and life sciences market.
Log in to access full profile ›Company Intelligence Q&A
- What is ProtAb's primary focus?
- ProtAb Ltd focuses on developing therapeutic agents that modulate cytokine regulation to address autoimmune and inflammatory diseases.
- What is Prozumab?
- Prozumab is ProtAb's monoclonal antibody with a novel mechanism of action, currently in late-stage preclinical development for inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA).
- Who founded ProtAb?
- ProtAb was founded by Yaakov Naparstek in August 2005.
- Which investors have participated in ProtAb's funding rounds?
- ProtAb has received funding from investors including Hadasit Bio-Holdings, Clal Biotechnology Industries (CBI), and Pontifax.
- What is ProtAb's current product development stage?
- ProtAb's product, Prozumab, is currently in late-stage preclinical development for the treatment of inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA). This stage involves extensive laboratory testing to assess safety and efficacy before human trials.